Congenital muscular dystrophy: Clinical and pathologic study of 50 patients with the classical (occidental) merosin-positive form

Neurology

Volumn 46, Issue 3, 1996, Pages 815-818

  Kobayashi, O ^a   Hayashi, Y ^a   Arahata, K ^a   Ozawa, E ^a   Nonaka, I ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; MEROSIN;

ARTICLE; BRAIN ATROPHY; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPMENTAL DISORDER; FEMALE; FETUS MOVEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; MOTOR DEVELOPMENT; MUSCLE BIOPSY; MUSCULAR DYSTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; WALKING;

EID: 0029877803     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.3.815     Document Type: Article

References (18)

1. Tome FMS, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with merosin deficiency. CR Acad Sci III 1994; 317:351-357.
2. Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle. Neuromuscul Disord 1995;5:301-305.
3. Tinsley JM, Blake DJ, Zuellig RA, et al. Increasing complexity of the dystrophin-associated protein complex. Proc Natl Acad Sci USA 1994;91:8307-8313.
4. Dubowitz V. Definition of pathological changes seen in muscle biopsies. In: Dubowitz V, ed. Muscle biopsy: a practical approach. 2nd ed. London: Baillière Tindall, 1985:82-128.
5. Yamamoto H, Hagiwara Y, Mizuno Y, et al. Heterogeneity of dystrophin-associated proteins. J Biochem (Tokyo) 1993;114: 132-139.
6. Mizuno Y, Yoshida M, Nonaka I, et al. Expression of utrophin (dystrophin-related protein) and dystrophin-associated glycoproteins in muscles from patients with Duchenne muscular dystrophy. Muscle Nerve 1994;17:206-216.
7. Osawa M. A genetical and epidemiological study on congenital progressive muscular dystrophy (Fukuyama type). J Tokyo Women's Med Coll (Tokyo) 1978;48:204-241.
8. Fukuyama Y, Osawa M, Suzuki H. Congenital progressive muscular dystrophy of the Fukuyama type: clinical, genetic and pathological considerations. Brain Dev 1981;3:1-29.
9. Toda T, Segawa M, Nomura Y, et al. Localization of a gene for Fukuyama type congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 1993;5:283-286.
10. Dubowitz V. Exciting new developments in CMD. Presented at the International Symposium on Congenital Muscular Dystrophies (satellite symposium of the 8th International Congress on Neuromuscular Diseases), Tokyo, Japan, July 1994.
11. Segawa M. Clinical studies on congenital muscular dystrophy with mental retardation and facial muscle involvement [in Japanese]. No To Hattatsu 1970;2:439-451.
12. McMenamin JB, Becker LE, Murphy EG. Congenital muscular dystrophy: a clinicopathologic report of 24 cases. J Pediatr 1982;100:692-697.
13. Brooke MH, Fenichel GM, Griggs RC, et al. Clinical investigation in Duchenne dystrophy. 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
14. Zellweger H, Durnin R, Simpson J. The diagnostic significance of serum enzymes and electrocardiogram in various muscular dystrophies. Acta Neurol Scand 1972;48:87-101.
15. Bushby KMD, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. J Neurol 1993;240:98-104.
16. Nonaka I, Chou SM. Congenital muscular dystrophy. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology, vol 41. Amsterdam: North-Holland Publishing, 1979:27-50.
17. Nonaka I, Sugita H, Takada K, Kumagai K. Muscle histochemistry in congenital muscular dystrophy with central nervous system involvement. Muscle Nerve 1982;5:102-106.
18. Nonaka I, Takagi A, Sugita H. The significance of type 2C fibers in Duchenne muscular dystrophy. Muscle Nerve 1981;4: 326-333.